NASDAQ:ABCM

Abcam Stock Forecast, Price & News

$19.89
+0.19 (+0.96 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$19.55
Now: $19.89
$19.97
50-Day Range
$19.22
MA: $21.24
$24.30
52-Week Range
$17.71
Now: $19.89
$24.69
Volume97,927 shs
Average Volume180,565 shs
Market Capitalization$4.51 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. Further, the company offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.
Abcam logo

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ABCM
CUSIPN/A
CIKN/A
Phone44 1223 696 000
Employees1,492
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$4.51 billion
Next Earnings DateN/A
OptionableNot Optionable

Headlines

Abcam (NASDAQ:ABCM) Shares Gap Down to $19.89
April 6, 2021 |  americanbankingnews.com
Short Interest in Abcam plc (NASDAQ:ABCM) Expands By 63.1%
March 31, 2021 |  americanbankingnews.com
Abcam is Now Oversold
March 8, 2021 |  nasdaq.com
Abcam plc reports 1H results
March 8, 2021 |  seekingalpha.com
Abingdon Healt. Regulatory News
February 10, 2021 |  lse.co.uk
Abingdon Health signs collaboration and co-marketing agreement with Abcam
February 9, 2021 |  markets.businessinsider.com
Abcam plc Half Year Trading Update
January 11, 2021 |  finance.yahoo.com
Abcam PLC ADR
November 15, 2020 |  barrons.com
ABCM.OQ - Abcam Plc Profile | Reuters
November 13, 2020 |  reuters.com
See More Headlines

MarketRank

Overall MarketRank

1.52 out of 5 stars

Medical Sector

488th out of 2,010 stocks

Biotechnology Industry

22nd out of 143 stocks

Analyst Opinion: 3.2Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -
$19.89
+0.19 (+0.96 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ABCM News and Ratings via Email

Sign-up to receive the latest news and ratings for ABCM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Abcam (NASDAQ:ABCM) Frequently Asked Questions

Is Abcam a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Abcam in the last twelve months. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Abcam stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABCM, but not buy additional shares or sell existing shares.
View analyst ratings for Abcam
or view top-rated stocks.

What stocks does MarketBeat like better than Abcam?

Wall Street analysts have given Abcam a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Abcam wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Abcam?

Abcam saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 63,600 shares, an increase of 63.1% from the February 28th total of 39,000 shares. Based on an average trading volume of 205,800 shares, the short-interest ratio is currently 0.3 days.
View Abcam's Short Interest
.

What price target have analysts set for ABCM?

7 analysts have issued twelve-month price targets for Abcam's shares. Their forecasts range from $20.00 to $25.00. On average, they expect Abcam's share price to reach $22.00 in the next twelve months. This suggests a possible upside of 10.6% from the stock's current price.
View analysts' price targets for Abcam
or view top-rated stocks among Wall Street analysts.

Who are Abcam's key executives?

Abcam's management team includes the following people:
  • Mr. Alan Thomas Hirzel BS, MS, MBA, CEO & Exec. Director (Age 53)
  • Mr. Michael Shaun Baldock, CFO & Director (Age 56)
  • Mr. Mark Dermody, Interim CIO
  • James Staveley, VP of Investor Relations
  • Marc Perkins, Gen. Counsel & Company Sec.
  • Dr. Cheri L. Walker, Sr. VP of Corp. Devel.
  • Mr. Nick Skinner, Sr. VP of HR
  • Mr. Mark Bushfield, Sr. VP of Research & Innovation
  • Ms. Kirstie Speck BBusSc, Head of Consumer Insights
  • Ms. Yvonne Chien, Sr. VP of Customer Experience

Who are some of Abcam's key competitors?

When did Abcam IPO?

(ABCM) raised $149 million in an initial public offering (IPO) on Thursday, October 22nd 2020. The company issued 9,000,000 shares at a price of $16.52 per share. Morgan Stanley, BofA Securities, SVB Leerink, Lazard and William Blair served as the underwriters for the IPO.

What is Abcam's stock symbol?

Abcam trades on the NASDAQ under the ticker symbol "ABCM."

When does the company's lock-up period expire?

Abcam's lock-up period expires on Tuesday, April 20th. Abcam had issued 8,945,218 shares in its IPO on October 22nd. The total size of the offering was $156,541,315 based on an initial share price of $17.50. After the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

How do I buy shares of Abcam?

Shares of ABCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Abcam's stock price today?

One share of ABCM stock can currently be purchased for approximately $19.89.

How much money does Abcam make?

Abcam has a market capitalization of $4.51 billion.

How many employees does Abcam have?

Abcam employs 1,492 workers across the globe.

What is Abcam's official website?

The official website for Abcam is www.abcam.com.

How can I contact Abcam?

The company can be reached via phone at 44 1223 696 000.


This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.